Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver

In breve · dalla fonte (EU-Startups)

Di cosa si tratta

Cambridge-based Undecimal Bio, a spin-out from Eleven Therapeutics advancing targeted delivery of siRNA therapeutics, today announced a €16 million ($18 million) Seed financing round to expand DELiveri, its proprietary AI-enabled platform for identifying conjugates that can direct RNA medicines to defined cell types. The round was co-led by 4BIO Capital and IQ Capital, with participation […] The post Undecimal Bio lands €16 million to develop targeted RNA medicines beyond the liver appeared first on EU-Startups .

Anteprima pubblicata dalla testata nel proprio feed. DuoBiz non ripubblica l'articolo né le immagini: per il testo completo, i dati e le dichiarazioni vai alla fonte.